AMO Pharma amo-pharma.com


Public lists: Rare Diseases (230)

AMO Pharma is working to identify and advance promising therapies for the treatment of serious and debilitating diseases in patient populations with significant areas of unmet need, including rare genetic diseases. AMO Pharma is currently advancing two investigational therapies for treatment of fragile X syndrome and myotonic dystrophy, and is in the process of licensing additional development-stage products in diverse areas including autism and other CNS disorders.

AMO Pharma is working to identify and advance promising therapies for the treatment of serious and debilitating diseases in patient populations with significant areas of unmet need, including rare genetic diseases. AMO Pharma is currently advancing t...Show all

Company (Alive / Active)

Phone: +44 (0) 1483 319070

Fax:

152-160 City Road

London, EC1V 2NX
England, United Kingdom

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
AMO Pharma $60M Jan 10, 2020

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related AMO Pharma Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Undisclosed InvestorsOtherSeries B
Woodford Investment ManagementMutual FundOxford, England, United KingdomShareholder Liquidity, Series A
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Methods of treating phelan mcdermid syndrome using farnesyl dibenzodiazepinones Oct 25, 2018 Application